fda - Search News

FDA Approves 1st Non-Opioid Pain Drug in 20 Years

CNN on MSN · 4h

FDA approves first new type of pain medication in 25 years

The US Food and Drug Administration signed off Thursday on the first new type of pain reliever to be approved in more than two decades. The drug, suzetrigine, is a 50-milligram prescription pill that’s taken every 12 hours after a larger starter dose.

Time on MSN · 8h

FDA Approves the First Non-Opioid Pain Drug in 20 Years

The prescription pills, sold under the brand name Journavx and made by Vertex Pharmaceuticals, are taken twice a day and represent the first new class of pain medications in 20 years—and the first non-opioid painkiller since that class first appeared on the market in the 1980s.

The Associated Press on MSN · 9h

FDA Approves New Painkiller That Shows Promise and Challenges of Opioid Alternatives

U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated with opioids

type 2 diabetes, chronic kidney disease and FDA

CNN on MSN · 2d

FDA approves Ozempic to reduce risks from chronic kidney disease in diabetes patients

Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the US Food and Drug Administration to reduce certain risks associated with chronic kidney disease,

US FDA approves Novo Nordisk's Ozempic to cut risk of diabetic kidney disease progression

The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart problems in diabetes patients with chronic kidney disease (CKD),

U.S. News & World Report · 1d

FDA Approves Ozempic to Protect Kidneys in Patients With Type 2 Diabetes

Doctors already use Ozempic to manage type 2 diabetes and reduce the risk of heart disease in patients with diabetes. This move, as reported by The Times, was based on research sh

FDA, Axsome and migraine

US FDA approves Axsome Therapeutics' migraine drug

The U.S. Food and Drug Administration has approved Axsome Therapeutics' migraine treatment, the company said on Thursday.

Business Insider · 12h

Axsome Therapeutics announces FDA approval of Symbravo

Axsome Therapeutics (AXSM) announced that the U.S. FDA has approved Symbravo for the acute treatment of migraine with or without aura in

Investing.com on MSN · 11h

FDA approves new migraine treatment SYMBRAVO

NEW YORK - Axsome Therapeutics, Inc. (NASDAQ:AXSM), a $5.28 billion biopharmaceutical company with impressive 51% revenue growth over the last twelve months, announced the U.S. Food and Drug Administration (FDA) has approved SYMBRAVO®,

FDA upgrades recall of Lay's potato chips

USA Today · 1d

Lay's potato chips recall upgraded to FDA's most serious level. Is Ohio affected?

The FDA elevated Lay's Classic Potato Chips to the highest risk level. Here what to know, and whether the recall impacts Ohio.

Fortune on MSN · 1d

FDA reclassifies Lay’s potato chips recall to the highest risk level, warning the chips could cause ‘serious adverse health consequences or death’

The FDA has raised the risk level on a recall of Lay’s potato chips to the highest level, warning the recalled product could cause death. The chips were originally recalled last month for containing undeclared milk.

New York Daily News · 11h

Lay’s recall increased to highest level, could cause ‘death’: FDA

The agency on Monday assigned a Class I recall to 6,344 bags of Lay’s Classic Potato Chips due to “undeclared milk,” which means that milk wasn’t listed on the product ingredients. The oversight could result in “death,

13h

US FDA Identifies Cybersecurity Risks in Certain Patient Monitors

(Reuters) - The U.S. Food and Drug Administration (FDA) said on Thursday it had identified three cybersecurity risks ...

1don MSN

Chocolate Recall Update As FDA Sets Highest Risk Level for 9 States

A recall which was issued across nine states has now been given the highest risk classification by the federal agency.

Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results